2024 ICD-10-CM Diagnosis Code C64.9

Approximate Synonyms

The following clinical terms are approximate synonyms or lay terms that might be used to identify the correct diagnosis code:

• 11p partial monosomy syndrome
• Acquired cystic disease associated renal cell carcinoma
• Adrenal gland involved by direct invasion of renal tumor
• Chromophobe renal cell carcinoma
• Clear cell carcinoma of kidney
• Clear cell papillary renal cell carcinoma
• Clear cell sarcoma of kidney
• Collecting duct carcinoma of kidney
• Cutaneous leiomyoma
• Cystadenocarcinoma of kidney
• Cystic partially differentiated nephroblastoma of kidney
• Cystic renal cell carcinoma of kidney
• Deletion of part of chromosome 11
• Familial renal cell carcinoma
• Global developmental delay, lung cysts, overgrowth, Wilms tumor syndrome
• Hereditary leiomyomatosis and renal cell carcinoma
• Hereditary papillary renal cell carcinoma
• Hereditary primary clear cell renal cell carcinoma
• Local recurrence of malignant tumor of kidney
• Malignant cystic nephroma
• Malignant granular cell tumor
• Malignant granular cell tumor
• Malignant tumor of kidney
• Malignant tumor of kidney parenchyma
• Metastatic clear cell renal cell carcinoma
• Metastatic renal cell carcinoma
• Metastatic renal cell carcinoma
• Metastatic renal cell carcinoma
• Metastatic renal cell carcinoma to kidney
• Metastatic renal cell carcinoma to kidney except renal pelvis
• MiT family translocation renal cell carcinoma
• Mucinous tubular and spindle cell renal carcinoma
• National Wilms Tumor Study Group Stage finding
• National Wilms Tumor Study Group Stage finding
• National Wilms Tumor Study Group Stage finding
• National Wilms Tumor Study Group Stage finding
• National Wilms Tumor Study Group Stage finding
• National Wilms Tumor Study Group Stage I
• National Wilms Tumor Study Group Stage II
• National Wilms Tumor Study Group Stage III
• National Wilms Tumor Study Group Stage IV
• National Wilms Tumor Study Group Stage V
• Nephroblastoma
• Nephroblastoma
• Papillary cystadenocarcinoma of kidney
• Papillary renal cell carcinoma
• Primary cystadenocarcinoma of kidney
• Primary cystic renal cell carcinoma of kidney
• Primary malignant granular cell tumor
• Primary malignant neoplasm of kidney
• Primary papillary cystadenocarcinoma of kidney
• Primary renal cell carcinoma
• Primary renal granular cell carcinoma
• Primary transitional cell carcinoma of kidney
• Renal cell carcinoma
• Renal cell carcinoma of kidney except renal pelvis
• Renal cell carcinoma of kidney except renal pelvis
• Renal granular cell carcinoma
• Renal medullary carcinoma
• Renal tumor extends beyond Gerota's fascia macroscopically
• Renal tumor extends into major vein macroscopically
• Renal tumor finding
• Renal tumor finding
• Renal tumor finding
• Renal tumor finding
• Renal tumor finding
• Renal tumor finding
• Renal tumor invades renal vein macroscopically
• Renal tumor invasion into adrenal gland macroscopically
• Renal tumor invasion into perinephric tissue macroscopically
• Sarcoma of kidney
• Transitional cell carcinoma of kidney
• Tubulocystic renal cell carcinoma
• WAGR syndrome

Clinical Information

• WAGR Syndrome

  a contiguous gene syndrome associated with hemizygous deletions of chromosome region 11p13. the condition is marked by the combination of wilms tumor; aniridia; genitourinary abnormalities; and intellectual disability.

• Metastatic Clear Cell Renal Cell Carcinoma

  a clear cell renal cell carcinoma that has spread from its original site of growth to other anatomic sites.

C64.9 is grouped with Diagnostic Related Groups - MS-DRG Mapping

Diagnostic Related Groups (DRGs) are a classification system used to group together diagnosis codes for the purpose of reimbursement and healthcare management. DRGs are used to standardize the way hospitals and other providers are paid for inpatient services. In this system patients are grouped together based on their principal diagnosis in areas referred to as Major Diagnostic Categories (MDC). Once a patient is assigned a particular diagnostic category, providers receive a predetermined payment rate for the services rendered. This reimbursement rate is often fixed and is meant to cover the cost of care for that patient. Reimbursement is also affected by the relative weight of a diagnostic related group based on the severity of a patient's illness and the associated cost of care during hospitalization.

Diagnostic related groups encourage healthcare providers to focus on quality and efficiency in patient care while managing costs effectively. The diagnosis code is present in the following groups for version MS-DRG V41.0 applicable from 10/01/2023 through 09/30/2024.

MS-DRG	MS-DRG Title	MCD	Relative Weight
656	KIDNEY AND URETER PROCEDURES FOR NEOPLASM WITH MCC	11	3.1376
657	KIDNEY AND URETER PROCEDURES FOR NEOPLASM WITH CC	11	1.8442
658	KIDNEY AND URETER PROCEDURES FOR NEOPLASM WITHOUT CC/MCC	11	1.4804

The relative weight of a diagnostic related group determines the reimbursement rate based on the severity of a patient's illness and the associated cost of care during hospitalization.

Convert C64.9 to ICD-9-CM

• ICD-9-CM Code: 189.0 - Malig neopl kidney
  Approximate Flag - The approximate mapping means there is not an exact match between the ICD-10 and ICD-9 codes and the mapped code is not a precise representation of the original code.

Patient Education

Kidney Cancer

You have two kidneys. They are fist-sized organs on either side of your backbone above your waist. The tubes inside filter and clean your blood, taking out waste products and making urine. Kidney cancer forms in the lining of tiny tubes inside your kidneys.

Kidney cancer becomes more likely as you age. Risk factors include smoking, having certain genetic conditions, and misusing pain medicines for a long time.

You may have no symptoms at first. They may appear as the cancer grows. See your health care provider if you notice:

• Blood in your urine
• A lump in your abdomen
• Weight loss for no reason
• Pain in your side that does not go away
• Loss of appetite

Tests to diagnose kidney cancer include blood, urine, and imaging tests. You may also have a biopsy.

Treatment depends on your age, your overall health and how advanced the cancer is. It might include surgery, chemotherapy, or radiation, biologic, or targeted therapies. Biologic therapy boosts your body's own ability to fight cancer. Targeted therapy uses drugs or other substances that attack specific cancer cells with less harm to normal cells.

NIH: National Cancer Institute

[Learn More in MedlinePlus]

Kidney (Renal Cell) Cancer—Patient Version

Learn about kidney tumor risk factors, symptoms, tests to diagnose, factors affecting prognosis, staging, and treatment.
[Learn More in MedlinePlus]

Code History

• FY 2024 - No Change, effective from 10/1/2023 through 9/30/2024
• FY 2023 - No Change, effective from 10/1/2022 through 9/30/2023
• FY 2022 - No Change, effective from 10/1/2021 through 9/30/2022
• FY 2021 - No Change, effective from 10/1/2020 through 9/30/2021
• FY 2020 - No Change, effective from 10/1/2019 through 9/30/2020
• FY 2019 - No Change, effective from 10/1/2018 through 9/30/2019
• FY 2018 - No Change, effective from 10/1/2017 through 9/30/2018
• FY 2017 - No Change, effective from 10/1/2016 through 9/30/2017
• FY 2016 - New Code, effective from 10/1/2015 through 9/30/2016. This was the first year ICD-10-CM was implemented into the HIPAA code set.